Advocacy intelligence hub — real-time data for patient organizations
ERIBULIN MESYLATE: FDA approved
Canadian Cancer Trials Group — PHASE1
National Cancer Institute (NCI) — PHASE1
University of Calgary — EARLY_PHASE1
University of Calgary — EARLY_PHASE1
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — NA
Tecelra: FDA approved
treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A02:03P, or -A*02:06P positive and whose tumor expresses the melanoma-associated antigen A4 (MAGE-A4) antigen as determined by FDA-approved or cleared companion diagnostic devices
AHS Cancer Control Alberta — EARLY_PHASE1
National University of Singapore — PHASE4
University of Michigan — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Lartruvo
Eli Lilly and Company
Tecelra
USWM CT, LLC
Patient Assistance Programs1
Votrient
Novartis Pharmaceuticals Corp
Tecelra
(afamitresgene autoleucel)Orphan drugUSWM CT, LLC
12.1 Mechanism of Action TECELRA is a genetically modified autologous T cell immunotherapy consisting of CD4 and CD8 positive T cells transduced with ...
Lartruvo
(olaratumab)Orphan drugEli Lilly and Company
Halaven
(eribulin mesylate)Orphan drugEisai Inc.
12.1 Mechanism of Action Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonprod...
Yondelis
(trabectedin)Orphan drugJanssen Research & Development, LLC
Alkylating Drug [EPC]
12.1 Mechanism of Action Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a ...
Votrient
(pazopanib)Orphan drugNovartis Pharmaceuticals Corp
12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, pl...
TECENTRIQ
(atezolizumab)Orphan drugstandardGenentech, Inc.
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action PD L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti...
Douglas S Hawkins
Children's Oncology Group
📍 Birmingham, Alabama
Abha A Gupta
Children's Oncology Group
Leo Mascarenhas, MD
Children's Oncology Group
📍 LOS ANGELES, CA
Michael V Ortiz
Pediatric Early Phase Clinical Trial Network
Central Contact
Astellas Pharma Global Development
Svetlana Kulyova, MD, Phd
Head of Children's Oncology Department